University of Oxford [clinicaltrials_resource:4fd6f7d59a501f9b8bac2be37914c43e]
Tim Maughan [clinicaltrials_resource:00f57eef42ae18e68e88fcc9fc5aafe1]Antonio Pellicer, MDPhD [clinicaltrials_resource:04d4442faff5f7e35e194ccdd801cc11]Catherine Harmer, DPhil [clinicaltrials_resource:063953da0c5da43e83b83a88ab325144]Jacinta O'Shea, Dr [clinicaltrials_resource:06cce5259bc381f3350ea372e450802f]Kate Watkins, PhD [clinicaltrials_resource:0797914c8b4015a29c2190aa5b7eca9e]Nicholas J White, PhD [clinicaltrials_resource:0b4374d50642ef139f3098f2f419938e]Lalitha Iyadurai [clinicaltrials_resource:0c272846d41070b683bc50742d027508]Matthew Craner, MBChB PhD [clinicaltrials_resource:0d560f5ee3b64f472ffe6f048d07be8c]Helen McShane, MD and PhD [clinicaltrials_resource:0d80df572de79952714b6efe5cafe3c2]Martin Landray [clinicaltrials_resource:10e7a656d83ad873fb12d3110ab03ecf]John R Geddes, MD FRCPsych [clinicaltrials_resource:145479fa8e17bcc3b041745199028c65]Helen McShane [clinicaltrials_resource:14b0b5498cc3632dd2a4810c71163765]Peter A Robbins, DPhil BM BCh [clinicaltrials_resource:14b32cf5ef97d14a1938726f0dc3bfec]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Tipu Aziz, MD [clinicaltrials_resource:154634bd0c62f07258aca944ba776f94]Sion Glyn-Jones, MA MBBS FRCS DPhil [clinicaltrials_resource:156739ef8550ccf2cc10b8e5550ec45d]Annabel H Nickol, MBBS PhD [clinicaltrials_resource:15679ed75834bc3e20edc7db6e0bd7a5]Robert E MacLaren, DPhil [clinicaltrials_resource:15a9a3604d80ae76aa3e894e6a96a9e6]Bee Wee, PhD [clinicaltrials_resource:15cb0e6a25693a3897d96061f7fe988e]Andrew J Pollard, FRCPCH, PhD [clinicaltrials_resource:170e1c59edd2beb79adad819f44c8b41]Ingrid Granne [clinicaltrials_resource:17bb40c079a2530464308b9e3ef8aaed]Catherine Harmer, DPhil [clinicaltrials_resource:17e6f6c9259cf7c37d9916562229662f]Mark R Middleton [clinicaltrials_resource:183bbd33dd9e8877ba7d98793c9a4396]Joanna Robson, MD [clinicaltrials_resource:18b43e4cc9c6343f2bf619933138eab9]John R Geddes, MD FRCPsych [clinicaltrials_resource:19975debd4bf7764d1d29462fabd7419]Kyle TS Pattinson, BM DPhil FRCA [clinicaltrials_resource:19d0219b3182726d2f3a865a40e3e9f4]Rose McGready, MD [clinicaltrials_resource:1bc02e1527c941a04f9880b6733654e4]Sion Glyn-Jones, MA MBBS FRCS DPhil [clinicaltrials_resource:1bdff223ad6b7be2d80e8161f812af60]Kyle TS Pattinson, BM DPhil FRCA [clinicaltrials_resource:1bff09846633154faecd236f286f398b]Mark R Middleton, PhD, FRCP [clinicaltrials_resource:1ca2fb9eca7f02ca4acd5f7b72b66a7b]Francois Nosten, MD [clinicaltrials_resource:1cfe0b3442a171b64147c828ded95afe]Tipu Aziz, MD [clinicaltrials_resource:1e64746a89f6fda9679f3fc2267fe86f]Leanne Hodson, PhD [clinicaltrials_resource:1f4a3a73d74511dcafccf9e51c0739cb]Guy Goodwin [clinicaltrials_resource:20d9aeb949ee5f12d62382084a9f17ba]Bass Hassan, BSc(Hon) BMBCh MRCP DPhil FRCP [clinicaltrials_resource:21603884500f864e8eb9275c798991df]Najib Rahman, DPhil [clinicaltrials_resource:21adebc42531670108db11b652d9505f]Eleanor Barnes, BSc MBBS PhD [clinicaltrials_resource:22aaf2f7fc1082cafc5da4226c58da97]I Z MacKenzie, FRCOG [clinicaltrials_resource:22e402bb1eb636fcea87a3a04829772b]Peter A Robbins, DPhil [clinicaltrials_resource:236fa1f9e2bb2092e1f92f075485ab94]Lucy Dorrell, Prof. [clinicaltrials_resource:23d3e37cd34c71b435fd4640213d1c1d]
affiliation [clinicaltrials_vocabulary:affiliation]
An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression [clinicaltrials:NCT00122083]clinicaltrials:NCT00124072clinicaltrials:NCT00125593clinicaltrials:NCT00131196clinicaltrials:NCT00135226Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6 [clinicaltrials:NCT00222547]Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction [clinicaltrials:NCT00222573]Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 [clinicaltrials:NCT00222612]Qidong Hepatitis B Intervention Study [clinicaltrials:NCT00222664]Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function [clinicaltrials:NCT00232531]clinicaltrials:NCT00299442Effect of Folic Acid Treatment in Coronary Artery Disease [clinicaltrials:NCT00300352]clinicaltrials:NCT00357682Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen [clinicaltrials:NCT00408668]Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study) [clinicaltrials:NCT00423280]Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis [clinicaltrials:NCT00433719]clinicaltrials:NCT00459264Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town [clinicaltrials:NCT00460590]clinicaltrials:NCT00461630Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines [clinicaltrials:NCT00480454]A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both [clinicaltrials:NCT00480558]Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia [clinicaltrials:NCT00493363]clinicaltrials:NCT00548444A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis [clinicaltrials:NCT00579956]clinicaltrials:NCT00638092A Study of MVA85A in Healthy Children and Infants [clinicaltrials:NCT00679159]clinicaltrials:NCT00682578A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV [clinicaltrials:NCT00731471]clinicaltrials:NCT00829660Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment [clinicaltrials:NCT00843570]Neonatal Sepsis and GBS Carriage Study [clinicaltrials:NCT00861055]clinicaltrials:NCT00883402Pilot Study: Age Extension of NHS Breast Screening Programme [clinicaltrials:NCT00890864]The Study of Chest Infections in Infants Living in a Refugee Camp on the Thai-Burmese Border [clinicaltrials:NCT00894764]Understanding the Immune Response to Meningitis Vaccines [clinicaltrials:NCT00901940]clinicaltrials:NCT00934492clinicaltrials:NCT00936767A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults [clinicaltrials:NCT00942071]Study of the Effects of Iron Levels on the Lungs at High Altitude [clinicaltrials:NCT00952302]Study of the Effects of Iron on Lung Blood Pressure at High Altitude [clinicaltrials:NCT00960921]
collaborator [clinicaltrials_vocabulary:collaborator]
Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer [clinicaltrials:NCT00003016]An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression [clinicaltrials:NCT00122083]clinicaltrials:NCT00124072clinicaltrials:NCT00125593clinicaltrials:NCT00131196clinicaltrials:NCT00135226Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6 [clinicaltrials:NCT00222547]Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction [clinicaltrials:NCT00222573]Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 [clinicaltrials:NCT00222612]Qidong Hepatitis B Intervention Study [clinicaltrials:NCT00222664]Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function [clinicaltrials:NCT00232531]clinicaltrials:NCT00299442Effect of Folic Acid Treatment in Coronary Artery Disease [clinicaltrials:NCT00300352]clinicaltrials:NCT00357682The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV [clinicaltrials:NCT00395720]Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen [clinicaltrials:NCT00408668]Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study) [clinicaltrials:NCT00423280]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. [clinicaltrials:NCT00423566]A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers [clinicaltrials:NCT00423839]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously [clinicaltrials:NCT00427453]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG [clinicaltrials:NCT00427830]Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis [clinicaltrials:NCT00433719]Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB. [clinicaltrials:NCT00456183]clinicaltrials:NCT00459264Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town [clinicaltrials:NCT00460590]The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries [clinicaltrials:NCT00461318]clinicaltrials:NCT00461630A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG [clinicaltrials:NCT00465465]Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines [clinicaltrials:NCT00480454]A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both [clinicaltrials:NCT00480558]A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers [clinicaltrials:NCT00480688]A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers [clinicaltrials:NCT00480714]Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia [clinicaltrials:NCT00493363]clinicaltrials:NCT00548444A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis [clinicaltrials:NCT00579956]clinicaltrials:NCT00638092A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination [clinicaltrials:NCT00653627]A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A [clinicaltrials:NCT00653770]Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine [clinicaltrials:NCT00654316]A Study of MVA85A in Healthy Children and Infants [clinicaltrials:NCT00679159]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Dr. Paul Montgomery, University of Oxford [clinicaltrials_resource:0c135c28708f1b1bb2505636225dcdb6]Ian MacKenzie, University of Oxford [clinicaltrials_resource:1061d24e50456e0c10cc3deb252caf79]Peter Friend / Professor of Transplantation, University of Oxford [clinicaltrials_resource:316551712f760e4a21f6f17bcba3f5ab]Centre for Tropical Diseases, University of Oxford [clinicaltrials_resource:474f1a80b62dba870037fa39ba36e3c7]Professor Rory Collins, University of Oxford [clinicaltrials_resource:52d87a08d08947b314a589d9da861d96]Prof Adrian Hill, University of Oxford [clinicaltrials_resource:68ae147f91a39abf9d888362c8107cbf]Mr Tim Child/Consultant Gynaecologist and Chief Investigator, University of Oxford [clinicaltrials_resource:7c1b7dfd6baada5eaa34e4e96cde144c]Ms Heather House, Head of Clinical Trials and Research Governance, University of Oxford [clinicaltrials_resource:89aa2cb4ef67094220befa16d0319213]Mrs Heather House, University of Oxford [clinicaltrials_resource:8a27f50afa5404f9e4a84807e0b9d916]Dr. Arjen Dondorp, University of Oxford [clinicaltrials_resource:8e605a81d361167e71ecca76c9fe8bbb]Heather House, University of Oxford [clinicaltrials_resource:a11fec69175c663d38ad05de6da4ea0e]Professor Andrew Pollard, Chief Investigator, University of Oxford [clinicaltrials_resource:d4c4aa85342712759ce8b4b9542d6fb8]Dr Helen McShane, University of Oxford [clinicaltrials_resource:e610cdcd0017dae22d6b6744f13a3405]Andrew Pollard, University of Oxford [clinicaltrials_resource:ff723f857e73c0a27016eeb236de5bc0]Professor Adrian Hill, University of Oxford [clinicaltrials_resource:ff7b003ac12eb120dbf41047c208074e]
organization [clinicaltrials_vocabulary:organization]
An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression [clinicaltrials:NCT00122083]clinicaltrials:NCT00124072clinicaltrials:NCT00125593clinicaltrials:NCT00131196clinicaltrials:NCT00135226Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6 [clinicaltrials:NCT00222547]Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction [clinicaltrials:NCT00222573]Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 [clinicaltrials:NCT00222612]Qidong Hepatitis B Intervention Study [clinicaltrials:NCT00222664]Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function [clinicaltrials:NCT00232531]clinicaltrials:NCT00299442Effect of Folic Acid Treatment in Coronary Artery Disease [clinicaltrials:NCT00300352]clinicaltrials:NCT00357682The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV [clinicaltrials:NCT00395720]Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen [clinicaltrials:NCT00408668]Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study) [clinicaltrials:NCT00423280]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. [clinicaltrials:NCT00423566]A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers [clinicaltrials:NCT00423839]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously [clinicaltrials:NCT00427453]A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG [clinicaltrials:NCT00427830]Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis [clinicaltrials:NCT00433719]Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB. [clinicaltrials:NCT00456183]clinicaltrials:NCT00459264Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town [clinicaltrials:NCT00460590]The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries [clinicaltrials:NCT00461318]clinicaltrials:NCT00461630A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG [clinicaltrials:NCT00465465]Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines [clinicaltrials:NCT00480454]A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both [clinicaltrials:NCT00480558]A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers [clinicaltrials:NCT00480688]A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers [clinicaltrials:NCT00480714]Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia [clinicaltrials:NCT00493363]clinicaltrials:NCT00548444A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis [clinicaltrials:NCT00579956]clinicaltrials:NCT00638092A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination [clinicaltrials:NCT00653627]A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A [clinicaltrials:NCT00653770]Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine [clinicaltrials:NCT00654316]A Study of MVA85A in Healthy Children and Infants [clinicaltrials:NCT00679159]clinicaltrials:NCT00682578
source [clinicaltrials_vocabulary:source]
University of Oxford [clinicaltrials_resource:4fd6f7d59a501f9b8bac2be37914c43e]
Bio2RDF identifier
4fd6f7d59a501f9b8bac2be37914c43e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4fd6f7d59a501f9b8bac2be37914c43e
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:4fd6f7d59a501f9b8bac2be37914c43e
title
University of Oxford
@en
type
label
University of Oxford [clinicaltrials_resource:4fd6f7d59a501f9b8bac2be37914c43e]
@en